Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors
Source: OncLive, November 2024
Victor Moreno, MD, PhD, medical oncologist, director, Clinical Research, START Madrid-Fundación Jimenez Diaz (FJD), discusses insights into the pharmacodynamic data for CLN-619, a novel humanized IgG1 antibody designed to bind to MICA and MICB, in patients with advanced solid tumors. Findings were presented by Moreno and colleagues during the 2024 SITC Annual Meeting.
This analysis stemmed from patients treated during a phase 1 trial (NCT05117476), which is evaluating CLN-619 as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors. Prior data showed that both the monotherapy and combination regimens demonstrated safety and elicited objective responses.
The pharmacodynamic analysis involved the collection of paired biopsies before and after treatment, which allowed investigators to assess immune response activation in the peripheral blood and the tumor microenvironment, Moreno begins. This analysis included 12 paired biopsies from patients.